Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Mixed Phenotype Acute Leukemia that Evolved from Myelodysplastic Syndrome with Excess Blasts.

Kim M, Zang DY, Lee J, Park JY, Chung Y, Lee YK.

Lab Med. 2019 Aug 30. pii: lmz054. doi: 10.1093/labmed/lmz054. [Epub ahead of print]

PMID:
31504737
2.

The effects of crizotinib in a transgenic Drosophila model expressing the human TPM4-ALK fusion gene or TPM4.

Kim YJ, Cho AR, Sul HJ, Kim B, Kim AY, Kim HS, Seo JB, Koh Y, Zang DY.

Biol Open. 2019 Jul 5;8(7). pii: bio044362. doi: 10.1242/bio.044362.

3.

Effect of pharmacokinetic model misspecification on antibiotic probability of target attainment predicted by Monte Carlo simulation
.

Kim SW, Kim DJ, Zang DY, Lee DH.

Int J Clin Pharmacol Ther. 2019 Jul;57(7):362-374. doi: 10.5414/CP203446.

PMID:
31094317
4.

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer.

Kim TY, Han HS, Lee KW, Zang DY, Rha SY, Park YI, Kim JS, Lee KH, Park SH, Song EK, Jung SA, Lee N, Kim YH, Cho JY, Bang YJ.

Gastric Cancer. 2019 Apr 3. doi: 10.1007/s10120-019-00958-4. [Epub ahead of print]

PMID:
30945121
5.

INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification.

Sohn SH, Kim B, Sul HJ, Kim YJ, Kim HS, Kim H, Seo JB, Koh Y, Zang DY.

BMC Res Notes. 2019 Mar 11;12(1):125. doi: 10.1186/s13104-019-4163-x.

6.

A Myelodysplastic Syndrome with Concurrent Basophilia and Eosinophilia Lacking Oncogenic Mutations in 54 Relevant Genes.

Kim M, Zang DY, Han B, Lee J, Chung Y, Park CJ, Lee YK.

Clin Lab. 2019 Jan 1;65(1). doi: 10.7754/Clin.Lab.2018.180729.

PMID:
30775878
7.

Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis.

Kim HS, Kim JH, Jang HJ, Han B, Zang DY.

J Cancer. 2019 Jan 1;10(1):20-27. doi: 10.7150/jca.28204. eCollection 2019.

8.

Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer.

Kim JW, Kim JG, Kang BW, Chung IJ, Hong YS, Kim TY, Song HS, Lee KH, Zang DY, Ko YH, Song EK, Baek JH, Koo DH, Oh SY, Cho H, Lee KW.

Cancer Res Treat. 2019 Jan;51(1):223-239. doi: 10.4143/crt.2018.073. Epub 2018 Oct 19.

9.

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review.

Kim HS, Kim JH, Jang HJ, Han B, Zang DY.

Int J Mol Sci. 2018 Aug 26;19(9). pii: E2529. doi: 10.3390/ijms19092529. Review.

10.

A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01).

Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY.

Oncologist. 2019 Jan;24(1):18-e24. doi: 10.1634/theoncologist.2018-0142. Epub 2018 Aug 20.

11.

A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03.

Kim SY, Joo J, Kim TW, Hong YS, Kim JE, Hwang IG, Kim BG, Lee KW, Kim JW, Oh HS, Ahn JB, Zang DY, Kim DY, Oh JH, Baek JY.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):889-899. doi: 10.1016/j.ijrobp.2018.04.013. Epub 2018 Apr 12.

PMID:
29976501
12.

Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.

Lee SE, Choi SY, Kim SH, Jootar S, Kim HJ, Sohn SK, Park JS, Kim SH, Zang DY, Oh SJ, Kim DW.

Leuk Res. 2018 Jul;70:100-105. doi: 10.1016/j.leukres.2018.06.002. Epub 2018 Jun 7.

PMID:
29908417
13.

Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function.

Kim SW, Choe S, Kim DJ, Zang DY, Lee DH.

Ther Drug Monit. 2018 Aug;40(4):425-434. doi: 10.1097/FTD.0000000000000528.

14.

Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial.

Lee KW, Zang DY, Ryu MH, Kim KH, Kim MJ, Han HS, Koh SA, Park JH, Kim JW, Nam BH, Choi IS.

Contemp Clin Trials Commun. 2017 Aug 18;8:55-61. doi: 10.1016/j.conctc.2017.08.006. eCollection 2017 Dec.

15.

Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.

Noh H, Jung SY, Kwak JY, Kim SH, Oh SJ, Zang DY, Lee S, Park HL, Jo DJ, Shin JS, Do YR, Kim DW, Lee JI.

Cancer Med. 2018 May;7(5):1766-1773. doi: 10.1002/cam4.1436. Epub 2018 Mar 25.

16.

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).

Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK.

Gastric Cancer. 2018 Sep;21(5):819-830. doi: 10.1007/s10120-018-0806-1. Epub 2018 Feb 9.

PMID:
29427038
17.

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.

Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY.

Cancer Res Treat. 2019 Jan;51(1):1-11. doi: 10.4143/crt.2018.028. Epub 2018 Feb 5.

18.

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.

Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK.

Gastric Cancer. 2018 Sep;21(5):802-810. doi: 10.1007/s10120-018-0794-1. Epub 2018 Jan 25.

PMID:
29372461
19.

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.

Yoo C, Han B, Kim HS, Kim KP, Kim D, Jeong JH, Lee JL, Kim TW, Kim JH, Choi DR, Ha HI, Seo J, Chang HM, Ryoo BY, Zang DY.

Cancer Res Treat. 2018 Oct;50(4):1324-1330. doi: 10.4143/crt.2017.526. Epub 2018 Jan 8.

20.

The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study.

Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS.

Korean J Intern Med. 2019 Jan;34(1):165-177. doi: 10.3904/kjim.2016.348. Epub 2017 Nov 28.

21.

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.

Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW.

Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22.

22.

Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.

Lee JH, Kim H, Joo YD, Lee WS, Bae SH, Zang DY, Kwon J, Kim MK, Lee J, Lee GW, Lee JH, Choi Y, Kim DY, Hur EH, Lim SN, Lee SM, Ryoo HM, Kim HJ, Hyun MS, Lee KH; Cooperative Study Group A for Hematology.

J Clin Oncol. 2017 Aug 20;35(24):2754-2763. doi: 10.1200/JCO.2017.72.8618. Epub 2017 Jun 20.

PMID:
28632487
23.

Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.

Kim JW, Lee KW, Kim KP, Lee JH, Hong YS, Kim JE, Kim SY, Park SR, Nam BH, Cho SH, Chung IJ, Park YS, Oh HS, Lee MA, Kang HJ, Park YI, Song EK, Han HS, Lee KT, Shin DB, Kang JH, Zang DY, Kim JH, Kim TW.

Oncologist. 2017 Mar;22(3):293-303. doi: 10.1634/theoncologist.2016-0166. Epub 2017 Feb 16.

24.

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

Kim BJ, Kim JH, Kim HS, Zang DY.

Oncotarget. 2017 Feb 21;8(8):13979-13985. doi: 10.18632/oncotarget.14704. Review.

25.

A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.

Han B, Jung JY, Kim HS, Cho JW, Kim KC, Lim H, Kang HS, Ha HI, Kim MJ, Kim JH, Choi DR, Jang G, Kim JH, Song H, Zang DY.

Cancer Chemother Pharmacol. 2016 Nov;78(5):949-958. Epub 2016 Sep 15.

PMID:
27628195
26.

Rapid CO breath test screening of drugs for protective effects on ribavirin-induced hemolysis in a rabbit model: a pilot study.

Ma YJ, Zhang HD, Wu CH, Zhu GL, Ji YQ, Huang JL, Du LT, Cao P, Zang DY, Ji KM.

J Breath Res. 2016 Aug 10;10(3):036010. doi: 10.1088/1752-7155/10/3/036010.

PMID:
27506143
27.

A Modified Carbon Monoxide Breath Test for Measuring Erythrocyte Lifespan in Small Animals.

Ma YJ, Zhang HD, Ji YQ, Zhu GL, Huang JL, Du LT, Cao P, Zang DY, Du JH, Li R, Wang L.

Biomed Res Int. 2016;2016:7173156. doi: 10.1155/2016/7173156. Epub 2016 May 12.

28.

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.

Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, Kim HJ, Kim SH, Zang DY, Oh S, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW.

Haematologica. 2016 Jun;101(6):717-23. doi: 10.3324/haematol.2015.139899. Epub 2016 Feb 17.

29.

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1.

Jung JY, Ryu MH, Ryoo BY, Han B, Cho JW, Lim MS, Lim H, Kang HS, Kim MJ, Ha HI, Song H, Kim JH, Kim HS, Kang YK, Zang DY.

Gastroenterol Res Pract. 2016;2016:6857625. doi: 10.1155/2016/6857625. Epub 2015 Dec 29.

30.

Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: A Multicenter Retrospective Study.

Park YH, Yi HG, Kim CS, Hong J, Park J, Lee JH, Kim HY, Kim HJ, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY; Gyeonggi/Incheon Branch, The Korean Society of Hematology.

Acta Haematol. 2016;135(3):162-71. doi: 10.1159/000442703. Epub 2016 Jan 16.

PMID:
26771656
31.

Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.

Noh H, Park MS, Kim SH, Oh SJ, Zang DY, Park HL, Cho DJ, Kim DW, Lee JI.

Leuk Lymphoma. 2016 Aug;57(8):1856-64. doi: 10.3109/10428194.2015.1113278. Epub 2015 Dec 15.

PMID:
26666371
32.

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.

Kim JH, Zang DY, Chung IJ, Cho SH, Park KU, Oh HS, Lee KH, Lee BH, Kim MJ, Park CK, Han B, Kim HS, Choi DR, Song HH, Jung JY.

J Cancer. 2015 Aug 29;6(10):1041-8. doi: 10.7150/jca.12819. eCollection 2015.

33.

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, Kim YH, Park JO, Chun HG, Zang DY, Fielding A, Rowbottom J, Hodgson D, O'Connor MJ, Yin X, Kim WH.

J Clin Oncol. 2015 Nov 20;33(33):3858-65. doi: 10.1200/JCO.2014.60.0320. Epub 2015 Aug 17.

PMID:
26282658
34.

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).

Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, Cho SH, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK; SOS study investigators.

Ann Oncol. 2015 Oct;26(10):2097-101. doi: 10.1093/annonc/mdv316. Epub 2015 Jul 27.

PMID:
26216386
35.

Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.

Lee KW, Lee KH, Zang DY, Park YI, Shin DB, Kim JW, Im SA, Koh SA, Yu KS, Cho JY, Jung JA, Bang YJ.

Oncologist. 2015 Aug;20(8):896-7. doi: 10.1634/theoncologist.2015-0202. Epub 2015 Jun 25.

36.

Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.

Kim HS, Ryu MH, Zang DY, Ryoo BY, Yang DH, Cho JW, Lim MS, Kim MJ, Han B, Choi DR, Kim JH, Jung JY, Song H, Park CK, Kang YK.

Gastric Cancer. 2016 Apr;19(2):579-585. doi: 10.1007/s10120-015-0503-2. Epub 2015 May 22.

PMID:
25997815
37.

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.

Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, Kim YK, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW.

Leuk Lymphoma. 2016 Feb;57(2):341-347. doi: 10.3109/10428194.2015.1049166. Epub 2015 Jun 12.

PMID:
25947037
38.

A satisfaction survey on cancer pain management using a self-reporting pain assessment tool.

Lim SN, Han HS, Lee KH, Lee SC, Kim J, Yun J, Park S, Park M, Choe Y, Ryoo HM, Lee K, Cho D, Zang DY, Choi J.

J Palliat Med. 2015 Mar;18(3):225-31. doi: 10.1089/jpm.2014.0021. Epub 2015 Feb 4.

PMID:
25650504
39.

The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma.

Kim HY, Kim JS, Choi DR, Kim HS, Kwon JH, Jang GD, Kim JH, Jung JY, Song HH, Lee YK, Min SK, Hwang HS, Kim HJ, Zang DY, Kim HJ.

Cancer Res Treat. 2015 Jul;47(3):458-64. doi: 10.4143/crt.2014.091. Epub 2014 Nov 24.

40.

A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.

Choi DR, Yoon SN, Kim HS, Kim JH, Kim KY, Kim BC, Choi YK, Kim JB, Han B, Song HH, Zang DY.

Cancer Chemother Pharmacol. 2015 Mar;75(3):639-43. doi: 10.1007/s00280-015-2688-9. Epub 2015 Jan 29.

PMID:
25630415
41.

Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.

Kim HS, Kim HY, Zang DY, Oh HS, Jeon JY, Cho JW, Park CK, Kim JH, Kim MJ, Ha HI, Kim JH, Han B, Song H, Kwon JH, Choi DR, Jung JY.

Cancer Chemother Pharmacol. 2015 Apr;75(4):711-8. doi: 10.1007/s00280-015-2687-x. Epub 2015 Jan 29.

PMID:
25630414
42.

Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.

Kim H, Lee WS, Lee KH, Bae SH, Kim MK, Joo YD, Zang DY, Jo JC, Lee SM, Lee JH, Lee JH, Kim DY, Ryoo HM, Hyun MS, Kim HJ; CoOperative Study Group A for Hematology (COSAH).

Ann Hematol. 2015 May;94(5):739-46. doi: 10.1007/s00277-014-2268-9. Epub 2014 Dec 13.

PMID:
25501820
43.

Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis.

Hwang IG, Song HS, Lee MA, Nam EM, Lim J, Lee KH, Lee KT, Zang DY, Jang JS.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1291-6. doi: 10.1007/s00280-014-2608-4. Epub 2014 Oct 18.

PMID:
25326056
44.

Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer.

Kim HS, Kim JW, Kim JH, Choi DR, Han AR, Kim MJ, Kim BC, Zang DY.

Oncology. 2015;88(2):69-75. doi: 10.1159/000367810. Epub 2014 Oct 1.

PMID:
25277674
45.

Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach.

Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, Kim JM, Kim YI, Ryu KW, Kong SH, Kim HI, Jung HY, Kim YS, Zang DY, Cho JY, Park JO, Lim DH, Jung ES, Ahn HS, Kim HJ.

J Gastric Cancer. 2014 Jun;14(2):87-104. doi: 10.5230/jgc.2014.14.2.87. Epub 2014 Jun 30. Review.

46.

Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis.

Yi HG, Lee MH, Kim CS, Hong J, Park J, Lee JH, Han BR, Kim HY, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY; Gyeonggi/Incheon Branch, The Korean Society of Hematology.

Blood Res. 2014 Jun;49(2):95-9. doi: 10.5045/br.2014.49.2.95. Epub 2014 Jun 25.

47.

Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.

Kim SJ, Cheong JW, Kim DY, Lee JH, Lee KH, Kim YK, Kim HJ, Song IC, Jo DY, Lee JO, Bang SM, Park J, Lee JH, Lee WS, Joo YD, Maeng CH, Yoon HJ, Lee NR, Kwak JY, Kim KH, Won JH, Han BR, Zang DY, Moon JH, Sohn SK, Bae SH, Ryoo HM, Kim SY, Lee MH, Min YH; Korean Society of Hematology AML/MDS Working Party.

Int J Hematol. 2014 Aug;100(2):141-51. doi: 10.1007/s12185-014-1617-8. Epub 2014 Jul 5.

PMID:
24996615
48.

The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.

Jung JY, Kim HY, Han B, Choi DR, Zang DY, Kim HJ.

Biomed Res Int. 2014;2014:237698. doi: 10.1155/2014/237698. Epub 2014 Jun 4.

49.

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW.

Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4.

50.

[Synopsis on clinical practice guideline of gastric cancer in Korea: an evidence-based approach].

Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, Kim JM, Kim YI, Ryu KW, Kong SH, Kim HI, Jung HY, Kim YS, Zang DY, Cho JY, Park JO, Lim DH, Jung ES, Ahn HS, Kim HJ; Committee on Stomach Cancer Guideline Development.

Korean J Gastroenterol. 2014 Feb;63(2):66-81. Review. Korean.

Supplemental Content

Support Center